1 – 2 of 2
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Use of flutemetamol F18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment
(
- Contribution to journal › Article
- 2010
-
Mark
F-18-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial
(
- Contribution to journal › Article